Beamr video compression achieves up to 50% improvement for AVs
RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage, has initiated preclinical studies for a new intranasal delivery system for Benzodiazepines (BZDs), commonly used in treating acute repetitive seizures (ARS) and status epilepticus. The company’s proprietary drug delivery platform, known as Trap and Target™ (T&T), is designed to facilitate rapid and targeted seizure rescue therapy.
Epilepsy, a neurological disorder affecting around 50 million people globally according to the World Health Organization, often sees patients struggling with the control of ARS and the adverse effects of current treatments. The acute repetitive seizures market was valued at approximately $3.15 billion in 2024, with projections indicating growth at a compound annual growth rate (CAGR) of 12.7% from 2025 to 2030. Additionally, the global epilepsy treatment devices market is expected to expand from roughly $526.8 million in 2023 to about $787.3 million by 2033, growing at a CAGR of 4.1%. Despite operating in this growing market, InvestingPro analysis reveals Polyrizon has faced challenges, with its stock price declining over 51% in the past six months, though showing a notable 27% recovery in the past week. Subscribers to InvestingPro can access 5 additional key insights about PLRZ’s market position and growth potential.
The collaboration for these studies includes Professor Fabio Sonvico from the University of Parma, a leading expert in intranasal and pulmonary drug delivery solutions and a member of Polyrizon’s Scientific Advisory Board. The research will evaluate the drug loading capacity, release kinetics, nasal deposition, and stability of a model molecule emulating the behavior of intranasal BZDs.
BZDs are established first-line drugs for seizure treatment, acting by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at the GABA-A receptor in the central nervous system. Intranasal delivery offers advantages over traditional methods, such as ease of use and accessibility, enabling emergency responders, caregivers, and individuals to administer medication rapidly in out-of-hospital settings.
Tomer Izraeli, CEO of Polyrizon, expressed optimism about the potential of their intranasal delivery platform to provide a faster, safer, and more accessible solution for managing acute seizures outside clinical environments.
Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, forming a barrier in the nasal cavity against viruses and allergens. Their Capture and Contain™ hydrogel technology, composed of naturally occurring building blocks, aims to function as a biological mask by creating a containment barrier in the nasal cavity. The company is also developing its C&C hydrogel technology for intranasal drug delivery.
This article is based on a press release statement from Polyrizon Ltd. and does not include any promotional content or endorsement of the company’s claims.
In other recent news, Polyrizon Ltd. has announced advancements in its preclinical studies for an intranasal formulation of Naloxone, aimed at enhancing the drug’s delivery through its Trap and Target™ (T&T) platform. This development is part of a collaboration with Professor Fabio Sonvico from the University of Parma, focusing on improving the bioavailability and effectiveness of Naloxone, a critical medication for reversing opioid overdoses. Additionally, Polyrizon has entered into a partnership with an unnamed biotech company to develop an intranasal formulation for psychedelic-based treatments, utilizing its proprietary hydrogel technology. Under this partnership, Polyrizon will lead the formulation development, while the partner company will finance the research and development process. In a related move, Polyrizon has filed a divisional patent application in Israel for its T&T platform, which aims to protect its advanced intranasal drug delivery system. This patent filing complements a recent U.S. patent application covering aspects of Polyrizon’s core technologies. These recent developments underscore Polyrizon’s commitment to advancing its intranasal drug delivery platforms and securing intellectual property rights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.